Related Experiment Video
Updated: Sep 19, 2025
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.8K
Severe transient neonatal hyperinsulinism: First Peruvian case series.
Manuel André Virú-Loza1, Francesca Bermudez-Paredes2, Isabel Milagros Arauco-Carhuas2
1Unidad de Revisiones Sistemáticas y Meta-análisis, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.
SAGE Open Medical Case Reports
|June 16, 2025
Summary
Congenital hyperinsulinism causes severe hypoglycemia in children. Diazoxide effectively treated Peruvian infants with transient hyperinsulinism, showing manageable side effects.
Area of Science:
- Pediatric Endocrinology
- Neonatal Medicine
- Pharmacology
Background:
- Congenital hyperinsulinism (CHI) is a leading cause of pediatric hypoglycemia, risking significant brain damage.
- Transient forms of CHI, including those from perinatal stress, are common.
- Diazoxide is the established first-line treatment for CHI.
Observation:
- Reports on diazoxide use in Peruvian pediatric patients with hyperinsulinism are limited.
- This study presents the first Peruvian case series of severe transient neonatal hyperinsulinism.
- Patients were treated with diazoxide, a crucial medication for managing hyperinsulinism.
Findings:
- The case series demonstrated a good response to diazoxide treatment in severe transient neonatal hyperinsulinism.
- Adverse effects associated with diazoxide were manageable.
- This highlights diazoxide's efficacy in the Peruvian pediatric population.
Implications:
- Diazoxide is an essential medication for treating congenital hyperinsulinism.
- Inclusion of diazoxide in Peru's national formulary is recommended for timely access.
- This case series supports broader implementation of diazoxide therapy for pediatric hyperinsulinism in Peru.
Related Concept Videos
01:20Pathophysiology of Diabetes
1.3K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.3K
01:16Insulin: Dosing Regimen and Adverse Effects
271
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
271
01:22Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
01:15Hypoglycemia and Glucagon
353
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
353
01:20Inborn Errors of Metabolism
249
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
249
01:22Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K